Form 4: Ocular Therapeutix CMO Granted Significant Equity Awards

Ocular Therapeutix's Chief Medical Officer, Nadia Waheed, received significant equity grants, including restricted stock units and stock options, effective January 2, 2026.

Summary

• Nadia Waheed, Chief Medical Officer of Ocular Therapeutix, Inc. (OCUL), was granted 79,112 restricted stock units (RSUs) on January 2, 2026.
• Each RSU represents a right to receive one share of the Corporation's common stock, vesting over three years, with 1/3 vesting on the one-year anniversary of the grant date and the remainder vesting annually thereafter.
• Additionally, Ms. Waheed was granted stock options to purchase 240,932 shares of common stock with an exercise price of $11.82 per share, also effective January 2, 2026.
• These stock options will vest over four years, with 1/48 vesting monthly beginning on the one-month anniversary of the grant date, and have an expiration date of January 1, 2036.
• Following these transactions, Ms. Waheed beneficially owns 326,280 shares of common stock and 240,932 stock options.
• The grants were made under the 2021 Stock Incentive Plan, as amended, and are subject to Ms. Waheed's continued service to the Corporation.

Sentiment

Score: 7

Explanation: The filing reports routine executive compensation in the form of equity grants, which is generally positive for executive retention and alignment with shareholder interests, but does not contain new operational or financial performance data.

Positives

• The equity grants align the Chief Medical Officer's financial interests with those of the shareholders, incentivizing long-term performance and retention.
• The grants represent a significant component of executive compensation, reflecting confidence in the executive's continued contribution to the company.

Future Outlook

The vesting schedules for both the restricted stock units (three years) and stock options (four years) indicate an expectation of continued service from the Chief Medical Officer, aligning her long-term incentives with the company's future performance.

Industry Context

Equity grants to key executives like the Chief Medical Officer are a standard practice in the biotechnology and pharmaceutical industries. This compensation structure is designed to attract, retain, and motivate top talent by linking their personal wealth directly to the company's stock performance and long-term success, which is crucial for companies like Ocular Therapeutix focused on drug development and commercialization.

Corporate Governance

Stakeholder Impact

• Shareholders: The equity grants align the Chief Medical Officer's incentives with shareholder value creation, potentially leading to better long-term performance.
• Employees: Standard executive compensation practices, including equity grants, can influence overall compensation philosophy and morale within the company.

Next Steps

• Vesting of 1/3 of the restricted stock units on the one-year anniversary of the grant date (January 2, 2027) and annually thereafter for two more years.
• Monthly vesting of stock options (1/48 per month) beginning one month after the grant date (February 2, 2026) for four years.

Key Dates

Keywords

Ocular Therapeutix, OCUL, Form 4, Insider Transaction, Equity Grant, Restricted Stock Units, RSU, Stock Options, Executive Compensation, Chief Medical Officer